Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 642 participants.

Also called NCT01841697

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 642 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01841697
  • EudraCT 2013-000059-42
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01841697. Randomized; double masking; primary purpose treatment. Start 2013-06-13 (actual); primary completion 2014-11-17 (actual). Results posted on 2015-11-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)
Intervention (Drug)
Omarigliptin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo to omarigliptin
Intervention (Drug)
Placebo to Sitagliptin
Intervention (Drug)
Open-label Metformin
Intervention (Drug)
Open-label Glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01841697
Content hash
30cdbbfc27b19c257aa783754f54b82c2388f253ca7d8d7da99da655cf2b405f